<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Mannkind Corp — News on 6ix</title>
<link>https://6ix.com/company/mannkind-corp</link>
<description>Latest news and press releases for Mannkind Corp on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 29 Apr 2026 20:01:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/mannkind-corp" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68359be278dffbe2df106ed2.webp</url>
<title>Mannkind Corp</title>
<link>https://6ix.com/company/mannkind-corp</link>
</image>
<item>
<title>MannKind to Report First Quarter 2026 Financial Results on May 6, 2026</title>
<link>https://6ix.com/company/mannkind-corp/news/mannkind-to-report-first-quarter-2026-financial-results-on-may-6-2026</link>
<guid isPermaLink="true">https://6ix.com/company/mannkind-corp/news/mannkind-to-report-first-quarter-2026-financial-results-on-may-6-2026</guid>
<pubDate>Wed, 29 Apr 2026 20:01:00 GMT</pubDate>
<description>DANBURY, Conn. and WESTLAKE VILLAGE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions for cardiometabolic and orphan lung diseases, announced today that it will report its first quarter 2026 financial results on Wednesday, May 6, 2026, after market close. The company will host a webcast beginning at 4:30 p.m. Eastern Time to review the financial</description>
</item>
<item>
<title>MannKind to Present New Data From Pediatric and Adult Studies of Afrezza® at ATTD 2026</title>
<link>https://6ix.com/company/mannkind-corp/news/mannkind-to-present-new-data-from-pediatric-and-adult-studies-of-afrezzar-at-attd-2026</link>
<guid isPermaLink="true">https://6ix.com/company/mannkind-corp/news/mannkind-to-present-new-data-from-pediatric-and-adult-studies-of-afrezzar-at-attd-2026</guid>
<pubDate>Mon, 09 Mar 2026 04:00:00 GMT</pubDate>
<description>Presentations highlight real‑world dosing and titration patterns in youth, and post‑prandial glucose management strategies using inhaled insulin in both</description>
</item>
<item>
<title>MannKind Announces Settlement of Convertible Senior Notes</title>
<link>https://6ix.com/company/mannkind-corp/news/mannkind-announces-settlement-of-convertible-senior-notes-17</link>
<guid isPermaLink="true">https://6ix.com/company/mannkind-corp/news/mannkind-announces-settlement-of-convertible-senior-notes-17</guid>
<pubDate>Thu, 05 Mar 2026 05:00:00 GMT</pubDate>
<description>DANBURY, Conn. and WESTLAKE VILLAGE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) today announced the settlement of the</description>
</item>
<item>
<title>MannKind to Participate in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/mannkind-corp/news/mannkind-to-participate-in-upcoming-investor-conferences-63</link>
<guid isPermaLink="true">https://6ix.com/company/mannkind-corp/news/mannkind-to-participate-in-upcoming-investor-conferences-63</guid>
<pubDate>Wed, 04 Mar 2026 05:00:00 GMT</pubDate>
<description>DANBURY, Conn. and WESTLAKE VILLAGE, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), announced today its attendance at two</description>
</item>
<item>
<title>MannKind Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/mannkind-corp/news/mannkind-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/mannkind-corp/news/mannkind-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update</guid>
<pubDate>Thu, 26 Feb 2026 05:00:00 GMT</pubDate>
<description>Conference call today at 9:00 am ET Q4 2025 revenues of $112M, +46% vs. Q4 2024 Furoscix® Q4 2025 net sales of $23M, +91% vs. Q4 2024 Afrezza® Q4 2025 net</description>
</item>
<item>
<title>MannKind to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference</title>
<link>https://6ix.com/company/mannkind-corp/news/mannkind-to-participate-in-the-oppenheimer-36th-annual-healthcare-life-sciences-conference</link>
<guid isPermaLink="true">https://6ix.com/company/mannkind-corp/news/mannkind-to-participate-in-the-oppenheimer-36th-annual-healthcare-life-sciences-conference</guid>
<pubDate>Thu, 19 Feb 2026 14:00:00 GMT</pubDate>
<description>DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), today announced Chief Executive Officer Michael Castagna, PharmD is scheduled to present and share business updates during the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 26, 2026, at 11:20 a.m. ET A link to the webcast of the presentation will be available on MannKind Corporation’s website at: https://investors.mannkindcorp.com/events-and-pres</description>
</item>
<item>
<title>MannKind to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026</title>
<link>https://6ix.com/company/mannkind-corp/news/mannkind-to-report-fourth-quarter-and-full-year-2025-financial-results-on-february-26-2026</link>
<guid isPermaLink="true">https://6ix.com/company/mannkind-corp/news/mannkind-to-report-fourth-quarter-and-full-year-2025-financial-results-on-february-26-2026</guid>
<pubDate>Wed, 18 Feb 2026 05:00:00 GMT</pubDate>
<description>DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a biopharmaceutical company dedicated to</description>
</item>
<item>
<title>MannKind Announces First Patient Enrolled in INHALE-1ST Pediatric Study Evaluating Afrezza® for Youth with Newly-Diagnosed Type 1 Diabetes (T1D)</title>
<link>https://6ix.com/company/mannkind-corp/news/mannkind-announces-first-patient-enrolled-110500536</link>
<guid isPermaLink="true">https://6ix.com/company/mannkind-corp/news/mannkind-announces-first-patient-enrolled-110500536</guid>
<pubDate>Mon, 09 Feb 2026 11:05:00 GMT</pubDate>
<description>Study to assess safety, efficacy and treatment experience of starting inhaled insulin in youth aged 10 to <18 years recently diagnosed with T1DDANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions for cardiometabolic and orphan lung diseases, today announced that the first patient has been enrolled in INHALE-1ST, a</description>
</item>
<item>
<title>MannKind Announces FDA Approval of Updated Afrezza® Label Providing Starting Dose Guidance when Switching from Multiple Daily Injections (MDI) or Insulin Pump Mealtime Therapy</title>
<link>https://6ix.com/company/mannkind-corp/news/mannkind-announces-fda-approval-updated-110500757</link>
<guid isPermaLink="true">https://6ix.com/company/mannkind-corp/news/mannkind-announces-fda-approval-updated-110500757</guid>
<pubDate>Mon, 26 Jan 2026 11:05:00 GMT</pubDate>
<description>Updated initial conversion table based on clinical trials in adults showing significantly improved mealtime glycemic excursions DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Jan. 26, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions for cardiometabolic and orphan lung diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved an update t</description>
</item>
<item>
<title>MannKind Provides Business Updates and 2026 Growth Drivers</title>
<link>https://6ix.com/company/mannkind-corp/news/mannkind-provides-business-updates-2026-130500090</link>
<guid isPermaLink="true">https://6ix.com/company/mannkind-corp/news/mannkind-provides-business-updates-2026-130500090</guid>
<pubDate>Thu, 08 Jan 2026 13:05:00 GMT</pubDate>
<description>DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions for cardiometabolic and orphan lung diseases, today provided business updates and outlined anticipated growth drivers for 2026, including progress across its commercial programs and clinical development initiatives. “MannKind closed 2025 on a high note, marked by</description>
</item>
<item>
<title>MannKind Shares FUROSCIX® Business Updates</title>
<link>https://6ix.com/company/mannkind-corp/news/mannkind-shares-furoscixr-business-updates-2025-12-23</link>
<guid isPermaLink="true">https://6ix.com/company/mannkind-corp/news/mannkind-shares-furoscixr-business-updates-2025-12-23</guid>
<pubDate>Tue, 23 Dec 2025 05:00:00 GMT</pubDate>
<description>FDA approves FUROSCIX® for use in pediatric patients weighing 43kg or aboveUSPTO issues five patents for FUROSCIX ReadyFlow™ Autoinjector WESTLAKE VILLAGE,</description>
</item>
<item>
<title>MannKind Announces U.S. FDA Accepts for Review its Supplemental New Drug Application (sNDA) of FUROSCIX ReadyFlow™ Autoinjector for the Treatment of Edema in Adults with Chronic Heart Failure or Chronic Kidney Disease</title>
<link>https://6ix.com/company/mannkind-corp/news/mannkind-announces-us-fda-accepts-review-its-supplemental-new-drug-application-snda</link>
<guid isPermaLink="true">https://6ix.com/company/mannkind-corp/news/mannkind-announces-us-fda-accepts-review-its-supplemental-new-drug-application-snda</guid>
<pubDate>Mon, 01 Dec 2025 05:00:00 GMT</pubDate>
<description>If approved, ReadyFlow Autoinjector would deliver an IV-equivalent diuretic dose (subcutaneous furosemide injection 80 mg/ml) in under 10 secondsWould</description>
</item>
<item>
<title>MannKind to Present at the Jefferies Global Healthcare Conference</title>
<link>https://6ix.com/company/mannkind-corp/news/mannkind-present-jefferies-global-healthcare-conference-2025-11-11</link>
<guid isPermaLink="true">https://6ix.com/company/mannkind-corp/news/mannkind-present-jefferies-global-healthcare-conference-2025-11-11</guid>
<pubDate>Tue, 11 Nov 2025 05:00:00 GMT</pubDate>
<description>DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) announced today that Michael Castagna,</description>
</item>
<item>
<title>MannKind Provides Update on Phase 3 ICoN-1 Trial of Nebulized Clofazimine for NTM Lung Disease</title>
<link>https://6ix.com/company/mannkind-corp/news/mannkind-provides-update-phase-3-icon-1-trial-nebulized-clofazimine-ntm-lung-disease</link>
<guid isPermaLink="true">https://6ix.com/company/mannkind-corp/news/mannkind-provides-update-phase-3-icon-1-trial-nebulized-clofazimine-ntm-lung-disease</guid>
<pubDate>Mon, 10 Nov 2025 05:00:00 GMT</pubDate>
<description>MannKind has made the decision to discontinue the ICoN-1 Phase 3 clinical trial evaluating nebulized clofazimine inhalation suspension for nontuberculous</description>
</item>
<item>
<title>MannKind Commemorates Alfred E. Mann’s 100th Birthday with New Scholarship Program Supporting Young Adults Living with Diabetes</title>
<link>https://6ix.com/company/mannkind-corp/news/mannkind-commemorates-alfred-e-manns-100th-birthday-new-scholarship-program</link>
<guid isPermaLink="true">https://6ix.com/company/mannkind-corp/news/mannkind-commemorates-alfred-e-manns-100th-birthday-new-scholarship-program</guid>
<pubDate>Thu, 06 Nov 2025 05:00:00 GMT</pubDate>
<description>$100,000 in scholarship funds to be distributed to at least 10 students living with diabetes pursuing higher education in life sciencesAlfred E. Mann</description>
</item>
<item>
<title>MannKind Corporation Reports Third Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/mannkind-corp/news/mannkind-corporation-reports-third-quarter-2025-financial-results-and-provides</link>
<guid isPermaLink="true">https://6ix.com/company/mannkind-corp/news/mannkind-corporation-reports-third-quarter-2025-financial-results-and-provides</guid>
<pubDate>Wed, 05 Nov 2025 05:00:00 GMT</pubDate>
<description>Conference call today at 9:00 am ET Q3 2025 revenues of $82.1M, +17% v. Q3 2024YTD 2025 revenues of $237.0M, +14% v. YTD 2024Completed acquisition of</description>
</item>
<item>
<title>MannKind Corporation to Hold 2025 Third Quarter Financial Results Conference Call on November 5, 2025</title>
<link>https://6ix.com/company/mannkind-corp/news/mannkind-corporation-hold-2025-third-quarter-financial-results-conference-call</link>
<guid isPermaLink="true">https://6ix.com/company/mannkind-corp/news/mannkind-corporation-hold-2025-third-quarter-financial-results-conference-call</guid>
<pubDate>Wed, 29 Oct 2025 04:00:00 GMT</pubDate>
<description>DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), announced today that its third quarter</description>
</item>
<item>
<title>MannKind Announces U.S. FDA Accepts for Review its Supplemental Biologics License Application (sBLA) for Inhaled Insulin (Afrezza) in Children and Adolescents Aged 4-17 Years Living with Diabetes</title>
<link>https://6ix.com/company/mannkind-corp/news/mannkind-announces-us-fda-accepts-review-its-supplemental-biologics-license</link>
<guid isPermaLink="true">https://6ix.com/company/mannkind-corp/news/mannkind-announces-us-fda-accepts-review-its-supplemental-biologics-license</guid>
<pubDate>Mon, 13 Oct 2025 04:00:00 GMT</pubDate>
<description>If approved, it would be the first needle-free insulin option for pediatric patients in 100+ years of insulin therapysBLA submission based on data from the</description>
</item>
<item>
<title>MannKind Completes Acquisition of scPharmaceuticals, Accelerating Revenue Growth in Cardiometabolic Care</title>
<link>https://6ix.com/company/mannkind-corp/news/mannkind-completes-acquisition-scpharmaceuticals-accelerating-revenue-growth-0</link>
<guid isPermaLink="true">https://6ix.com/company/mannkind-corp/news/mannkind-completes-acquisition-scpharmaceuticals-accelerating-revenue-growth-0</guid>
<pubDate>Tue, 07 Oct 2025 04:00:00 GMT</pubDate>
<description>DANBURY, Conn. and BURLINGTON, Mass., Oct. 07, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) successfully completed the previously announced</description>
</item>
<item>
<title>MannKind Appoints Dr. Ajay Ahuja as Executive Vice President and Chief Medical Officer</title>
<link>https://6ix.com/company/mannkind-corp/news/mannkind-appoints-dr-ajay-ahuja-executive-vice-president-and-chief-medical-officer</link>
<guid isPermaLink="true">https://6ix.com/company/mannkind-corp/news/mannkind-appoints-dr-ajay-ahuja-executive-vice-president-and-chief-medical-officer</guid>
<pubDate>Mon, 29 Sep 2025 04:00:00 GMT</pubDate>
<description>WESTLAKE VILLAGE, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization</description>
</item>
</channel>
</rss>